Zyprexa (Eli Lilly) Drug Overview & Outlook 2017/18-2026 - ResearchAndMarkets.com


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


The "Drug Overview: Zyprexa" report has been added to ResearchAndMarkets.com's offering.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment of schizophrenia. Eli Lilly subsequently pursued development in bipolar disorder and received the first approval for Zyprexa as a monotherapy in the treatment of manic and mixed episodes in 2000.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Zyprexa: Bipolar Disorder
  4. Zyprexa: Schizophrenia

List of Figures

Figure 1: Zyprexa for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for Zyprexa in bipolar disorder

Figure 3: Drug assessment summary for Zyprexa in bipolar disorder

Figure 4: Zyprexa for schizophrenia - SWOT analysis

Figure 5: Drug assessment summary of Zyprexa for schizophrenia

Figure 6: Drug assessment summary of Zyprexa for schizophrenia


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


Figure 7: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zyprexa bipolar disorder indication approvals

Table 2: Zyprexa drug profile

Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder

Table 4: Adverse reactions reported in =5% of patients in six-week clinical trials of Zyprexa as an adjunct to lithium or valproate in adult bipolar disorder (manic/mixed episodes)

Table 5: Key side effects reported in clinical trials of Zyprexa in bipolar disorder

Table 6: Zyprexa drug profile

Table 7: Zyprexa pivotal trial data in schizophrenia

Table 8: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country (NYSE:M), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/hhmvmg/zyprexa_eli?w=4


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: Press Releases